Ma­jor­i­ty of top-sell­ing Medicare drugs of­fer lit­tle added ben­e­fit to al­ter­na­tives, re­searchers find

When Medicare be­gins ne­go­ti­at­ing prices for some of the most ex­pen­sive drugs in 2026, Har­vard re­searchers are call­ing on CMS to en­sure they are not …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.